A new blood test developed by Mayo Clinic researchers can accurately detect early symptoms of Alzheimer's disease by examining two proteins (amyloid beta 42/40 and p-tau217) in blood plasma, showing high sensitivity and specificity, and has been approved by the US FDA.
Alzheimer’s blood test can spot people with early symptoms, study suggests
Alzheimer'sHealthMedical researchDementiaMental health
AI Summary
TL;DR: Key points with love ❤️A new blood test developed by Mayo Clinic researchers can accurately detect early symptoms of Alzheimer's disease by examining two proteins (amyloid beta 42/40 and p-tau217) in blood plasma, showing high sensitivity and specificity, and has been approved by the US FDA.
Trending- 1 2025-06-07: Article published
- 2 By 2029: Goal to bring blood tests for dementia diagnosis to the NHS
- Potential for quicker, easier, and more accessible diagnosis of Alzheimer's
- Improved patient care and access to treatments
- Ongoing research to validate the test in diverse populations and community settings
What: A new blood test for Alzheimer's disease, developed by Mayo Clinic researchers, can accurately detect early symptoms by examining amyloid beta 42/40 and p-tau217 proteins in blood plasma.
When: Published 2025-06-07. Study conducted recently. Goal for NHS by 2029.
Where: Mayo Clinic (US), UK (NHS, Alzheimer's Society, Alzheimer's Research UK).
Why: To provide a more convenient, cost-effective, and less invasive method for diagnosing Alzheimer's disease early, compared to existing methods like cerebrospinal fluid biomarkers.
How: The test measures levels of amyloid beta 42/40 and p-tau217 proteins in blood plasma. It showed 95% sensitivity and 82% specificity in a study of over 500 people.